Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • 5 hours ago

Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Sep 1, 2026

Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?

Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Sep 1, 2026

Can Bixlenvo Unlock New Growth for Gilead's HIV Business?

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

Zacks Investment Research • Sep 1, 2026

Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.

Zacks Investment Research • Aug 28, 2026

FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevention.

CNBC • Aug 27, 2026

US FDA approves Gilead's once-daily combination pill for HIV treatment

The U.S. ​Food and ‌Drug Administration has ​approved ​Gilead Sciences' once ⁠daily ​oral combination ​pill for treatment of ​adults ​whose HIV has ‌already ⁠been reduced to very ​low ​levels, ⁠the company ​said on ​Thursday.

Reuters • Aug 27, 2026

U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. This novel HIV t.

Business Wire • Aug 27, 2026

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Gilead reported big losses last quarter, but this could pave the way for its diversification into oncology. In the meantime, investors remain focused mostly on the main growth driver: HIV prevention medicines.

The Motley Fool • Aug 26, 2026

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday, September 9 at 11:00 AM Eastern Time Cantor Global Healthcare Conference on Thursday, September 10 at 10:55 AM Eastern Time Morgan Stanley Global Healthcare Conference on Tuesday, September 15 at 10:45 AM Eastern Time The live webcasts can be accessed at the company's investor.

Business Wire • Aug 26, 2026